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Abstract
Background: The ability to self-inject in patients with multiple sclerosis (MS) has been associated with a reduced
risk of missed injections and drug discontinuation, and a beneficial effect on patients’ independence. However,
injection anxiety, needle phobia and disease-related disability are major barriers to a patient’s ability to self-
administer treatment. Use of an autoinjector may improve patients’ ability to self-inject. This study evaluated the
safe and effective use of Avonex Pen™ (prefilled pen), a single use autoinjector, for intramuscular delivery of
interferon beta-1a (IM IFNb-1a, Avonex) in MS patients.
Methods: This was a Phase IIIb, open-label, single-country, multicenter trial in MS patients currently using IM IFNb-
1a prefilled syringes. Patients received weekly 30 mcg IM IFNb-1a treatment over 4 weeks. On Day 1, patients self-
administered IM IFNb-1a using a prefilled syringe at the clinic. On Day 8, patients received training on the prefilled
pen and self-administered IM IFNb-1a using the device. On Day 15, patients self-administered IM IFNb-1a at home
using the prefilled pen. A final injection occurred at the clinic on Day 22 when patients self-administered IM IFNb-
1a using the prefilled pen while clinic staff observed and completed a detailed questionnaire documenting
patients’ ability to self-inject with the device. Serum neopterin levels were evaluated pre and post-injection on
Days 1 and 8. Adverse events were monitored throughout.
Results: Seventy-one (96%) patients completed the study. The overall success rate in safely and effectively using
the prefilled pen was 89%. No device malfunctions occurred. One unsuccessful administration occurred at Day 22
due to patient error; no patient injury resulted. Patients gave the prefilled pen high ratings (8.7-9.3) on a 10-point
scale for ease of use (0 = extremely difficult, 10 = extremely easy). Ninety-four percent of patients preferred the
prefilled pen over the prefilled syringe. Induction of serum neopterin levels, serving as a biomarker for type 1
interferon action, was similar to that of the prefilled syringe. The prefilled pen demonstrated a safety profile
comparable to the prefilled syringe.
Conclusions: The prefilled pen is a safe and effective device for administration of IM IFNb-1a and represents an
alternative method for self-injection for MS patients using this therapy.
Trial registration: This study is registered at clinicaltrials.gov, identifier: NCT00828204
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Multiple sclerosis (MS) is a chronic inflammatory dis-
ease of the central nervous system that can lead to
extensive neurodegeneration and subsequent irreversible
disability. Symptoms of MS affect motor, sensory, visual,
and autonomic systems but are not limited to these
areas alone [1]. While there is no cure for MS, treat-
ment with disease modifying therapies (DMTs) can
reduce the frequency of relapses and disability asso-
ciated with the disease [2-5].
For patients prescribed injectable DMTs, self-adminis-
tration has been associated with a reduced risk of
missed injections and drug discontinuation, and a bene-
ficial effect on patients’ sense of independence [6-8].
However, patients with MS face a variety of challenges
that limit their ability to self-administer treatment [9].
Injection anxiety, including anticipation of pain, fear of
hitting bone, inability to complete the injection effec-
tively and fear of needle breakage, is an important bar-
rier to self-injection [10]. Needle phobia, a component
of injection anxiety, occurs in approximately 50% of
patients with MS and therefore presents a significant
concern for patients using injectable therapies [11].
Furthermore, as MS is a disease that affects the CNS,
additional challenges to self-injection develop as the dis-
ease progresses and disability accumulates. Impairment
of fine motor skills and decreased coordination present
obstacles to the independent use of self-injected MS
therapies [12].
The clinical importance of enabling self-injection is
supported by various studies that have shown that the
injection process can be made easier for patients
through the use of automated injectors [13-16]. Autoin-
jectors have been shown to improve treatment adher-
ence, reduce injection related adverse events (AEs) such
as pain, and decrease injection anxiety [17-19]. Given
these clinical benefits and recognizing the frequency at
which barriers to self-injection are encountered by MS
patients, including those using intramuscular interferon
beta-1a (IM IFNb-1a, Avonex) [11,20], it is evident that
a mechanism to facilitate a patient’s ability to self-inject
IM IFNb-1a is needed.
The Avonex Pen™ (prefilled pen) is a single use auto-
injector containing the commercially available Avonex
®
Prefilled Syringe for once-weekly intramuscular (IM)
injection. The prefilled pen has been developed as the
first IM autoinjector available for long-term treatment
with IM IFNb-1a. Features of the prefilled pen have
been specifically designed to overcome the barriers to
self-injection and facilitate the technical aspects of the
injection process. These features include a protective
sheath that conceals the needle within the device prior
to injection, automated needle insertion and medication
dispensing, a diameter and length designed to stabilize
the device during the injection process, a safety mechan-
ism which prevents accidental injection, and a visual
indicator to confirm the full dose has been administered.
The prefilled pen has the potential to improve injec-
tion methods and simplify the self-injection process,
thereby addressing an unmet need in patients using IM
IFNb-1a. This study was conducted to evaluate the safe
and effective use of the prefilled pen for IM delivery of
IFNb-1a in patients with MS.
Methods
Study Design
This was a Phase IIIb, open-label, single-arm, multicen-
ter study to evaluate the safe and effective use of the
prefilled pen. A total of 17 sites in the United States
participated. Investigators at each site obtained institu-
tional review board (IRB) approval for the study proto-
col. This study was performed in accordance with all
international, federal and local regulations, and written
informed consent was obtained from each patient prior
to eligibility evaluations. Study duration was 6 weeks,
including a 14-day screening period and a 4 week IM
IFNb-1a treatment period. There were a total of 9
scheduled clinic visits per patient.
Study Population
Study participants were 18 to 65 years of age. Eligibility
criteria required patients to have been self-administering
the prefilled syringes to treat MS for the 12 weeks prior
to the screening visit. Key exclusion criteria included
concomitant treatment with prescribed immunomodula-
tors or immunosuppressants, and unwillingness or
inability to comply with the requirements of the proto-
col, including the presence of any condition (physical,
mental, or social) that was likely to affect a patient’s
ability to return for follow up visits on schedule.
Device Description
The prefilled pen is shown in Figure 1. This device uses
two springs to deliver the IM IFNb- 1 ad o s e .T h ef i r s t
spring performs the needle insertion and the second
spring dispenses the medication. Activation of the sec-
ond spring is dependent upon the successful completion
of the first spring’s activity. The prefilled pen is 13.5 cm
in length and has a diameter of 1.5 cm. A 25 G × 5/8
inch (16 mm) needle, housed in a protective shield
within the device, is used to deliver the IM IFNb-1a
dose.
For the manual injection with the prefilled syringe
(Injection 1), patients used their own supply of IM
IFNb-1a prefilled syringes. The needle size used for
Injection 1 was not recorded for each patient since the
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syringe can vary between patients. A 23 G × 1.25 inch
(32 mm) needle is included in the commercially avail-
able IM IFNb- 1 ap r e f i l l e ds y r i n g ep a c k a g e ,h o w e v e ra
different needle size (25 G × 1 inch) is also approved
for use with the IM IFNb-1a prefilled syringe. The deci-
sion of which needle a patient should use is based on
the needs of the patient and left to the discretion of the
prescribing physician, per IM IFNb-1a prescribing
information.
Treatment
All patients received 30 mcg doses of IM IFNb-1a once
weekly over 4 weeks. Patients who were taking prophy-
lactic therapy for flu-like symptoms at the start of the
study continued the same medication and dose until
their participation in the study was completed. If MS
relapses occurred during the study, these were treated at
the Investigator’s discretion following standard medical
practice, as long as treatment did not involve any of the
protocol excluded concomitant medications. Treatment
for spasticity, fatigue, or other MS associated symptoms
was not restricted.
Treatment Schedule
Patients who met the eligibility criteria during the 14-
day screening period entered into a 4-week IM IFNb-1a
treatment period. Injection 1 took place on Day 1 and
was administered at the study clinic by the patient using
a prefilled syringe from their own supply of IM IFNb-1a
prefilled syringes and needles as prescribed by their
physician.
Injection 2 occurred on Day 8 and was administered at
the study clinic by the patient using the prefilled pen fol-
lowing training provided by the clinic site Trainer/Obser-
ver. During this injection, the Trainer/Observer observed
patient use of the prefilled pen and reinforced training as
needed. Injection 3 occurred on Day 15 and was self-
administered by the patient at home using the prefilled
pen. The final injection, Injection 4, occurred on Day 22
and was administered at the study clinic by the patient
using the prefilled pen. At this clinic visit the Trainer/
Observer observed patient use of the prefilled pen and
completed a detailed questionnaire documenting
patients’ ability to self-inject with the device. The Trai-
ner/Observer completed the observation in a hands off
manner; no assistance or correction was provided to the
patient during this final injection. In total, patients were
to receive one injection with the prefilled syringe and
three injections with the prefilled pen.
Evaluations were made at various time points through-
out the study. The treatment schedule and correspond-
ing evaluations are displayed in Table 1.
Study Endpoints
Primary
The primary assessment of the safe and effective use of
the prefilled pen was to evaluate the overall success rate
as measured by the proportion of patients who success-
fully used the device. Data for determining the overall
success rate were generated from an observation form
that was completed by the Trainer/Observer during the
final injection (Day 22). The observation form was com-
posed of a series of questions organized around the
three key steps of the injection process: device setup,
self-administration of injection, and capping and dispo-
sal of the device. All actions captured in the observation
form that would define the patient’s handling of the pre-
filled pen as a failure were pre-defined in the protocol.
Failure was further categorized as “failure patient
induced” or “failure-possible device malfunction.” Over-
all success was defined as no failures occurring during
the patient’s use of the device.
Additional
Additional endpoints in this study included patient
assessments, clinician assessments, a pharmacodynamic
evaluation, and safety monitoring.
Patient Preference Assessment A preference question-
naire was administered to the patients on the last clinic
visit (either Day 23 or the final visit if patient was with-
drawing early from the study). The questionnaire inves-
tigated whether patients preferred the prefilled pen or
the prefilled syringe, and scored patient preference for
specific features of the prefilled pen compared to the
prefilled syringe using a grading scale ranging from 0
(defined on the form as “much worse”)t o1 0( d e f i n e d
on the form as “much better”); definitions for integers
2-9 on the scale were not specified.
Patient Assessment of Injection Procedure The injec-
tion procedure was assessed by each patient in order to
evaluate whether patients experienced any difficulty with
the processes of preparing, injecting, removing, and dis-
posing after each of the 4 injections (Days 1, 8, 15, 22).
Patient Assessment of Injection Site Pain Injection site
pain was evaluated pre and post injection by patients for
each of the 4 injections (Days 1, 8, 15, 22). Pain was
evaluated on a scale from 0 (no pain) to 10 (extremely
painful).
Blue activation
button
Needle cover Foil Prefilled pen cover
Body Injector shield
(grooved area)
Tamper-evident
cap
Figure 1 Avonex Pen.
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Page 3 of 9Table 1 Treatment period and evaluation schedule
Screening visit Injection using the prefilled syringe Injections using the prefilled
pen
EOS or
EW
Clinic Clinic Clinic Clinic Clinic Clinic Clinic Home Clinic Clinic
14-day period Day 1 Day 2 Day 3 Day 8 Day 9 Day 10 Day 15 Day 22 Day 23
Treatment and evaluations Injection 1 Injection 2 Injection 3 Injection 4
Study enrollment x
Injection using the prefilled syringe x
Neopterin serum sample collection x
a x
b x
c x
a x
b x
c
Prefilled pen training x
Injection using the prefilled pen xx x
Patient assessment of the prefilled pen training materials x x x
Patient assessment of injection site pain x
d x
d x
d x
d
Patient assessment of ease of use x x x x
Patient assessment of injection procedure x x x x
Clinician assessment of injection site x
e xx
e xx
e x
Observation form x
Preference questionnaire x
Patient assessment and dosing information forms dispensed x
Concomitant therapy and adverse events Monitor and record throughout study
EOS, end of study; EW, early withdrawal.
aNeopterin samples were to be obtained 1 hour pre-injection.
bNeopterin serum samples were to be obtained 24 hours ± 2 hours post-injection.
cNeopterin serum samples were to be obtained 48 hours ± 2 hours post-injection.
dTo be completed within 1 hour before injection and also immediately after injection.
eClinician injection site assessment was to be performed within 1 hour before injection.
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9Patient Assessment of Ease of Use Patients evaluated
the “ease of use” for each of the 4 injections performed
(Days 1, 8, 15, 22) by using the Ease-of-Use Grading
Scale to indicate how easy it was for the patient to per-
form the injection. The scale ranged from 0 (extremely
difficult) to 10 (extremely easy).
Patient Assessment of Training Materials For each use
of the prefilled pen (Days 8, 15, 22), patients evaluated
how easy or difficult it was to read and understand the
training materials.
Clinician Injection Site Assessment Clinicians at the
study site assessed injection sites 1 hour before injection
and 24 hours following injection for each administration
that took place at the clinic (Days 1, 8, 22). The injec-
tion site was examined for erythema, induration, tem-
perature, and tenderness.
Pharmacodynamics In order to evaluate levels of neop-
terin, a well-established biological marker of pharmaco-
dynamic response to activation of the Type 1 interferon
receptor, blood samples were collected from patients
one hour prior to injection and 24 and 48 hours follow-
ing injection for Injection 1 (Day 1, prefilled syringe)
and Injection 2 (Day 8, prefilled pen).
Safety A d v e r s ee v e n t sw e r em o n i t o r e dt h r o u g h o u tt h e
study.
Statistical Analyses
A 10% dropout rate was assumed for this study. A sam-
ple size of 70 patients was required to provide a 95%
confidence interval of the success rate [82.6%, 97.4%]
based on the assumption that 90% of patients would
successfully use the prefilled pen. The population used
to evaluate the primary outcome consisted of those
patients who received Injection 1 with the prefilled syr-
inge, received at least one injection with the prefilled
pen, and had a completed observation form.
Summary and descriptive statistics were used in this
study. No formal statistical testing was preplanned in
the protocol.
Results
Patient demographics
Of the 74 enrolled patients, 64 (86%) were female. Mean
patient age was 49.6 years (range: 22 to 65 years). The
mean body mass index (BMI) of the study population
was 28.92 kg/m
2 (range: 17.9 to 42.2 kg/m
2).
Patient Exposure to Study Treatment
Of 74 enrolled patients, 71 patients (96%) completed the
study. All 74 enrolled patients received a self-injection
using the prefilled syringe. Two patients discontinued
from the study following the injection with the prefilled
syringe prior to receiving an injection with the prefilled
pen (one patient was withdrawn after missing two clinic
visits and the other patient was withdrawn due to a MS
relapse). Seventy two patients received at least one self-
injection with the prefilled pen and 71 patients com-
pleted all three injections with the device. One patient
completed the final injection but did not have a com-
pleted observation form. As a result, the observation
form was only completed for 70 patients. In total, 215
injections were administered with the prefilled pen.
Overall Success Rate
The overall injection success rate was 89% (62/70
patients). No failures due to device malfunction and no
damaged or bent needles were reported. Eight (11%)
patient induced failures occurred, the majority of which
took place during device setup (seven patients removed
the needle cap manually rather than by extending the
injector shield). None of these events resulted in patient
injury and all patients were able to complete administra-
tion with the prefilled pen. Patient-induced failures
resulting in the device becoming unusable occurred in
one patient. In this case the patient did not follow
instructions and removed the device from the thigh pre-
maturely before medication was administered; upon a
second attempt the patient was able to successfully
complete all steps of the injection process. Patient suc-
cess at each observation of self-administration using the
prefilled pen is described in Table 2.
Patient Preference Assessment
The majority (94%) of patients indicated a preference for
the prefilled pen over the prefilled syringe. Patients eval-
uated the prefilled pen in comparison to the prefilled
syringe using a grading scale ranging from 0 (much
worse) to 10 (much better). Across all domains, patient
preference for the prefilled pen was strong (Figure 2).
Patient preference was related to key features of the
injection process, including ease of holding and gripping
(mean score of 8.7), ease of injection (mean score of
9.2), level of pain (mean score of 8.3), level of indepen-
dence (mean score of 8.5), level of confidence (mean
score of 8.7), and needle anxiety (mean score of 9.0).
The most common reasons for patient preference for
the prefilled pen are listed in Figure 3.
Patient Assessment of Injection Site Pain
Following injection with the prefilled syringe, the mean
pain score was low, 1.7 (out of 10). The mean pain
score for each of the 3 injections with the prefilled pen
was also low: 1.0, 1.3, and 0.7 for injections on Days 8,
15, and 22, respectively.
Patient Assessment of Injection Procedure
Eighty-nine percent of patients reported having no diffi-
culty with administration using the prefilled syringe. For
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patients reported having no difficulty.
Patient Assessment of Ease of Use
The mean ease of use score for the injection adminis-
tered with the prefilled syringe was 8.1 (out of 10). For
each administration with the prefilled pen, the mean
ease of use score was as follows: 8.9 on Day 8, 8.7 on
Day 15, and 9.3 for the final injection with the prefilled
pen.
Patient Assessment of Training Materials
Patients referred to the written instructions and DVD
less with each subsequent injection using the prefilled
pen. Of the patients who used the written instructions
and DVD, the majority rated them as “very effective” in
educating on how to use the prefilled pen (90%-93% for
written instructions; 88%-90% for DVD instructions).
Clinician Injection Site Assessment
Clinical injection site assessments made before and after
injection were similar between the prefilled syringe and
the prefilled pen. For the majority of patients, the clini-
cian found no presence of induration, no temperature
variation, and no tenderness at the site following injec-
tion with the prefilled syringe or the prefilled pen. Mild
erythema was reported in 26% of patients after using
the prefilled syringe and in 25% and 23% of patients on
Days 8 and 22 after using the prefilled pen. Mild indura-
tion and mild tenderness were reported in less than 8%
of patients following injections with both the prefilled
syringe and the prefilled pen. There were no severe
reports of erythema, induration, tenderness and tem-
perature following any injection.
Table 2 Patient success at each self-administration step using the prefilled pen (analysis population, n = 70)
Steps in self-administration using the prefilled pen Patients who completed step correctly and in
an optional manner, n (%)
Device setup
Holds device in an upright position and removes tamper-evident cap 66 (94)
Holds device in an upright position and attaches needle 58 (83)
Extends injector shield all the way, while pointing device away from body 61 (87)
Injection
Places and holds prefilled pen perpendicularly to anterior lateral thigh (injection site) 68 (97)
Applies firm downward pressure on the body of the prefilled pen and releases the safety
lock and fires device by depressing blue activation button
65 (93)
Holds device for a count of 10 seconds before removing needle from thigh 67 (96)
Lifts device straight out, perpendicular to thigh 68 (97)
Visually confirms delivery via circular display window 58 (83)
Capping and disposal
Caps the device with blue cover 66 (94)
Does not hold blue cover in place while capping prefilled pen 63 (90)
Note: All data were captured in the observation form.
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Figure 2 Mean patient preference scores for prefilled pen vs.
the prefilled syringe on 7 domains relevant to self-injection
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0 (prefilled pen much worse) to 10 (prefilled pen much better).
Reduction in injection anxiety
Less time consuming
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Ease of injection
0 1 02 03 04 05 06 07 08 09 0
Figure 3 Most common reasons reported for preferring the
prefilled pen (analysis population, n = 70).
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Similar increases in mean neopterin serum levels were
observed over time following administration with the
prefilled pen (6.2 ng/ml before injection, 12.6 ng/mL 24
hours after injection, and 13.7 ng/mL 48 hours after
injection) as were seen with the injection using the pre-
filled syringe (5.6 ng/mL before injection, 10.0 ng/mL 24
hours after injection, and 11.0 ng/mL 48 hours after
injection). The mean neopterin induction ratios were
similar for injection with the prefilled syringe and the
prefilled pen (2.149 and 2.514, respectively).
Safety - Adverse Events
All patients who received at least one dose of IM IFNb-
1a using either the prefilled syringe or the prefilled pen
were included in the safety population. The overall inci-
dence of AEs in this study was low and rates were simi-
lar between the prefilled syringe and the prefilled pen.
One patient experienced a MS relapse during the study
period. Eleven percent of patients reported an adverse
event with use of the prefilled syringe (Day 1), and 17%,
18%, and 4% of patients reported an adverse event with
each injection using the prefilled pen (Days 8, 15, and
22). No safety concerns potentially associated with the
prefilled pen were observed. The incidence of injection
site reactions was low and pain was infrequently
reported with the prefilled pen (Table 3).
Discussion
This open-label study evaluated the safe and effective
use of the prefilled pen in patients currently self-admin-
istering IM IFNb-1a via the prefilled syringe. These
patients represent the population expected to use the
prefilled pen and as such, were believed to be well sui-
ted to evaluate the prefilled pen.
Safe and effective use of the prefilled pen was assessed
from data captured in the observation form completed
by the Trainer/Observer. The comprehensive list of
questions in the observation form was developed to
provide an overall evaluation of the patients’ ability to
properly self-inject with the device during the final
injection using the prefilled pen. There were no device
malfunctions and the overall success rate of the prefilled
pen was high (89%), demonstrating that it provides a
safe and effective alternative method of administering
IM IFNb-1a. Patients also gave high ratings to the
related training materials and injection procedure.
The prefilled pen was specifically designed to over-
come multiple challenges of self-injection faced by
patients with MS. Features designed to reduce injection
anxiety include a protective shield that conceals the nee-
dle and automated needle insertion and medication dis-
pensing, which reduces the number of steps involved in
the dosing process. Safety features include a mechanism
to prevent early injection as well as a visual indicator
that allows for confirmation of injection process com-
pletion. The diameter and length dimensions are
designed to help stabilize the device during the injection
process so as to improve ease of use for patients with
impaired motor coordination. In this study, 94% of
patients preferred the prefilled pen over the prefilled
syringe. Reasons for patient preference for the prefilled
pen were related to ease of holding and gripping, ease
of injection, level of pain, and needle anxiety, confirming
that the design of the prefilled pen was successful in
making the injection process easier. In addition,
although the study was not originally designed to com-
pare the prefilled syringe to the prefilled pen, a post hoc
paired t test was performed to compare the ease of use
assessment at Injection 1 (Day 1, with the prefilled syr-
inge) with Injection 4 (Day 22, with the prefilled pen).
Results demonstrated that patients found the prefilled
pen statistically significantly easier to use after 3 injec-
tions compared to the prefilled syringe after at least 12
uses, as required by study entry criteria (mean ease of
use scores 8.1 and 9.3, respectively).
Automated injection devices offer a means to poten-
tially reduce injection site pain. In this study, patient
assessment of pain was low for the injection with the
prefilled syringe (1.7 out of 10), and numerically lower
for each of the three injections with the prefilled pen. A
post hoc comparison of the pain assessment at Injection
1 (Day 1, with the prefilled syringe) and Injection 4
(Day 22, with the prefilled pen) was performed by paired
t t e s ta n ds h o w e dt h a tp a t i e n t s experienced statistically
significantly less pain with the prefilled pen by the third
use than with the prefilled syringe after at least 12 uses,
as required by study entry criteria (mean pain scores 1.7
and 0.7, respectively). The incidence of pain through
safety monitoring was also low for both methods of
administration. Seven percent of patients reported an
AE of pain related to use of the prefilled pen and none
of the reports were severe. In addition to pain
Table 3 The most common (≥3%) treatment-emergent
prefilled pen injection site-related adverse events
n %
Number of patients who received at least 1 injection with
prefilled pen
72 100
Injection site-related adverse event
Injection site pain 5 7
Injection site hematoma 4 6
Injection site erythema 2 3
Injection site hemorrhage 2 3
Injection site induration 2 3
Note: A patient was counted only once within each preferred adverse event
term.
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time points during the study by the clinician. Mild
erythema was observed at a similar frequency following
injection with the prefilled syringe and injection with
the prefilled pen. The incidence of other injection site
reactions such as temperature, induration, and tender-
ness were infrequent, and rates were similar for the two
injection methods.
Importantly, there were no new safety concerns raised
in this study. The safety profile observed with the pre-
filled pen was similar to the known safety profile of IM
IFNb-1a from the prescribing information and post mar-
keting data.
Although IM injections are frequently administered
via a manual syringe with a longer needle, the 25 G ×
5/8 inch (16 mm) needle was determined to be the
appropriate size for use with the prefilled pen. Earlier
development of the prefilled pen using a 23 G × 1.25
inch (30 mm) needle indicated that this length was not
appropriate for use with the device due to needle bends,
which did not occur in this study with use of the shorter
needle. The ability of the needle used in this study to
deliver an IM injection is supported by published
reports indicating that a 5/8 inch needle (16 mm) can
be expected to access the IM space in the majority of
patients when applied with a manual syringe [21-23].
Considering the compressive effects related to the force-
ful application of the prefilled pen to the cutaneous tis-
sue, the shorter needle is likely appropriate for general
use [22,24].
As discussed earlier, reduction in needle anxiety and
injection pain were amongst the subjective benefits spe-
cifically sought in the design of the prefilled pen. We
note that the shorter needle length of the prefilled pen
may, in addition to its other features, contribute to the
observed patient preferences for this device over the
prefilled syringe. Our observation that neopterin induc-
tion was similar following injection with the prefilled
syringe and with the prefilled pen further supports that
the 25 G × 5/8 inch (16 mm) needle is the appropriate
s i z et oe f f e c t i v e l yd e l i v e rt h ef u l ld o s eo fI MI F N b-1a
with the prefilled pen as designed.
There are limitations to consider when interpreting the
results of this study. First, we acknowledge that the ques-
tionnaires and assessments used in the study have not
been formally validated. However, they were specifically
developed to capture information relevant to the robust
evaluation of the safety and efficacy of the prefilled pen.
In addition, several features of the study design and
population should be emphasized. We enrolled only
patients actively interested in the prefilled pen. In this
regard, we are not able to speculate on the outcomes of
a similar study conducted in patients who were not
interested in a self-injection device. Given the nature of
the study, it was also impossible to blind patients and
study staff regarding injection method. As such, the data
derived from the subjective assessments made in this
study may partially reflect patients’ and clinicians’
expectations for the prefilled pen. The partial crossover
study design in which patients switched from injections
with the prefilled syringe to injections with the prefilled
pen (and not from the prefilled pen to the prefilled syr-
inge) does not allow us to exclude an impact of treat-
ment order on our findings. Additionally, patients
evaluated the prefilled syringe injection experience only
once, whereas they evaluated the prefilled pen injection
experience a total of three times. It could be argued that
patient responses may have varied when assessing the
different methods since there were repeat evaluations
for only one of the methods. However, since the patients
in the population selected for this study were currently
using the prefilled syringe, it is unlikely that the single
assessment of the prefilled syringe would have differed
significantly if that assessment had been repeated.
While we acknowledge that this study evaluated the
prefilled pen in patients currently self-administering IM
IFNb-1a via the prefilled syringe and therefore does not
address its suitability in treatment-naïve patients or
when utilized by caregivers, the patient preference and
ease of use results indicate the prefilled pen would also
be an attractive option for use in these populations.
Conclusions
Injection anxiety and physical limitations are major bar-
riers to self-injection for many patients with MS. These
barriers may contribute to poor treatment adherence
that may result in a reduction in the clinical benefits of
MS therapy.
Results from this study support the safe and effective
use of the prefilled pen for self-administration of IM
IFNb-1a by patients with MS. Patients preferred the pre-
filled pen over the prefilled syringe for reasons related to
ease of use, injection pain, needle anxiety, and sense of
independence. Data from this study demonstrate the
potential for the prefilled pen to fulfil an unmet need in
patients using IM IFNb-1a by offering an alternative
method for IM delivery that simplifies the injection pro-
cess. The prefilled pen provides patients the opportunity
to gain the clinical benefits of IM IFNb-1a treatment
while improving their ability to independently manage
their disease.
Acknowledgements
The authors thank Kimberly Cushing of Biogen Idec for her assistance in
writing the manuscript, and Infusion, An InforMed Group Company, for their
assistance in developing the graphics.
The authors would also like to thank the lead investigator and staff at each
study site: Jeffrey English, MD (MS Center of Atlanta, Atlanta, GA), Warren
Felton, III, MD (Virginia Commonwealth University Medical Center, Richmond,
Phillips et al. BMC Neurology 2011, 11:126
http://www.biomedcentral.com/1471-2377/11/126
Page 8 of 9VA), John Foley, MD (Rocky Mountain MS Clinic, Salt Lake City, UT), Lawrence
Goldstick, MD (Neurology Specialists, Inc., Dayton, OH), Mark Gudesblatt, MD
(Comprehensive Multiple Sclerosis Care Center, Patchogue, NY), Barry
Hendin, MD (Phoenix Neurological Associates LTD, Phoenix, AZ), David
Hojnacki, MD (Buffalo General Hospital, Buffalo, NY), William Honeycutt, MD
(Neurological Associates, P.A., Maitland, FL), DeRen Huang, MD (Neurology &
Neuroscience Associates, Inc., Akron, OH), Michael Kaufman, MD (Carolinas
Healthcare System Neuroscience & Spine Institute, Charlotte, NC), Kiren
Kresa-Reahl, MD (Capitol Neurology, Charleston, WV), Ellen Lathi, MD (Caritas
St. Elizabeth’s Medical Center, Boston, MA), Howard Rossman, D.O., F.A.C.N.
(Michigan Institute for Neurological Disorders, Farmington Hills, MI), James C.
Stevens, MD (Fort Wayne Neurological Center, Fort Wayne, IN).
This study was funded by Biogen Idec.
Author details
1Texas Neurology, 6301 Gaston Ave, West Tower, #100, Dallas, Texas, USA.
2MS Clinic of Central Texas, Central Texas Neurology Consultants, PA, 16040
Park Valley Drive, Building B, Suite 100, Round Rock, Texas, USA.
3Neurological Physicians of Arizona, Clinical Research Advantage, 726 N.
Greenfield Road, Suite 110, Gilbert, Arizona, USA.
4Biogen Idec Inc., 14
Cambridge Center, Cambridge, Massachusetts, USA.
Authors’ contributions
All authors contributed to the manuscript and have read and approved the
final version. JTP served as the principal investigator and participated in the
study design. JTP, EF, and WG served as study site investigators. DT
participated in the conduct of the study and data analysis. SL participated in
the study design and performed the statistical analysis. AD participated in
the data analysis.
Competing interests
JTP has participated in consulting and/or speakers’ bureau with Biogen Idec,
Genzyme, Novartis, and Teva Neuroscience, and has participated in clinical
research with Biogen Idec.
EF has participated in consulting and/or speakers’ bureau with Bayer, Biogen
Idec, EMD Serono, Genzyme, Opexa, Novartis, Pfizer, and Teva Neuroscience,
and has participated in research studies involving Biogen Idec, Eli Lilly, EMD
Serono, Genzyme, Ono, Roche, Sanofi Aventis, and Teva Neuroscience.
WG has participated in consulting, speakers’ bureaus, and clinical research
with Biogen Idec and Teva Neuroscience.
DT, SL, and AD are employees of Biogen Idec.
Received: 26 July 2011 Accepted: 14 October 2011
Published: 14 October 2011
References
1. Compston A, Coles A: Multiple sclerosis. Lancet 2008, 372:1502-1517.
2. The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in
relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter,
randomized, double-blind, placebo-controlled trial. Neurology 1993,
43:655-661.
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM,
Fischer JS, Goodkin DE, Granger CV, Simon JH, et al: Intramuscular
interferon beta-1a for disease progression in relapsing multiple sclerosis.
In Ann Neurol. Volume 39. The Multiple Sclerosis Collaborative Research
Group (MSCRG); 1996:285-294.
4. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW,
Panitch HS, Rose JW, Schiffer RB: Copolymer 1 reduces relapse rate and
improves disability in relapsing-remitting multiple sclerosis: results of a
phase III multicenter, double-blind placebo-controlled trial. In Neurology.
Volume 45. The Copolymer 1 Multiple Sclerosis Study Group;
1995:1268-1276.
5. PRISMS (Prevention of Relapses and Disability by Interferon b-1a
Subcutaneously in Multiple Sclerosis) Study Group: Randomised
doubleblind placebo-controlled study of interferon b-1a in relapsing/
remitting multiple sclerosis. Lancet 1998, 352:1498-504, [Erratum, Lancet
1999; 353:678.].
6. Mohr DC, Cox D, Merluzzi N: Self-injection anxiety training: a treatment
for patients unable to self-inject injectable medications. Mult Scler 2005,
11:182-185.
7. Buhse M: Efficacy of EMLA cream to reduce fear and pain associated
with interferon beta-1a injection in patients with multiple sclerosis. J
Neurosci Nurs 2006, 38:222-226.
8. Turner AP, Williams RM, Sloan AP, Haselkorn JK: Injection anxiety remains a
long-term barrier to medication adherence in multiple sclerosis. Rehabil
Psychol 2009, 54:116-121.
9. Patti F: Optimizing the benefit of multiple sclerosis therapy: the
importance of treatment adherence. Patient Prefer Adherence 2010, 4:1-9.
10. Cox D, Stone J: Managing self-injection difficulties in patients with
relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006, 38:167-171.
11. Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE: Injectable
medication for the treatment of multiple sclerosis: the influence of self
efficacy expectations and injection anxiety on adherence and ability to
self-inject. Ann Behav Med 2001, 23:125-132.
12. Lugaresi A: Addressing the need for increased adherence to multiple
sclerosis therapy: can delivery technology enhance patient motivation?
Expert Opin Drug Deliv 2009, 6:995-1002.
13. Rubin RR, Peyrot M: Quality of life, treatment satisfaction, and treatment
preference associated with use of a pen device delivering a premixed
70/30 insulin aspart suspension (aspart protamine suspension/soluble
aspart) versus alternative treatment strategies. Diabetes Care 2004,
27:2495-2497.
14. Summers KH, Szeinbach SL, Lenox SM: Preference for insulin delivery
systems among current insulin users and nonusers. Clin Ther 2004,
26:1498-1505.
15. Hornquist JO, Wikby A, Andersson PO, Dufva AM: Insulin-pen treatment,
quality of life and metabolic control: retrospective intra-group
evaluations. Diabetes Res Clin Pract 1990, 10:221-230.
16. Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J: A
randomized, multicentre, open-label, parallel-group trial of the
tolerability of interferon beta-1a (Rebif) administered by autoinjection or
manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005,
11:585-591.
17. Kozubski W: Autoinjector Improves Injection-related Tolerability Issues in
Patients with Multiple Sclerosis - Exploring the New ExtaviJect™ 30G
System for the Injection of Interferon Beta-1b. Eur Neurol Rev 2010,
5(2):77-81.
18. Lugaresi A, Durastanti V, Gasperini C, Lai M, Pozzilli C, Orefice G, Sotgiu S,
Pucci E, Ardito B, Millefiorini E: Safety and tolerability in relapsing-
remitting multiple sclerosis patients treated with high-dose
subcutaneous interferon-beta by Rebiject autoinjection over a 1-year
period: the CoSa study. Clin Neuropharmacol 2008, 31:167-172.
19. Brochet B, Lemaire G, Beddiaf A: Reduction of injection site reactions in
multiple sclerosis (MS) patients newly started on interferon beta 1b
therapy with two different devices. Rev Neurol (Paris) 2006, 162:735-740.
20. Freedman SM, Cox D, Rosebrough T: A prospective baseline versus on
treatment study assessing patient perceptions of using a smaller needle
when injecting intramuscular interferon beta-1 a (Avonex). J Neurosci
Nurs 2008, 40:350-355.
21. Poland GA, Borrud A, Jacobson RM, McDermott K, Wollan PC, Brakke D,
Charboneau JW: Determination of deltoid fat pad thickness. Implications
for needle length in adult immunization. JAMA 1997, 277:1709-1711.
22. Song TT, Nelson MR, Chang JH, Engler RJ, Chowdhury BA: Adequacy of the
epinephrine autoinjector needle length in delivering epinephrine to the
intramuscular tissues. Ann Allergy Asthma Immunol 2005, 94:539-542.
23. Gibney MA, Arce CH, Byron KJ, Hirsch LJ: Skin and subcutaneous adipose
layer thickness in adults with diabetes at sites used for insulin
injections: implications for needle length recommendations. Curr Med
Res Opin 2010, 26:1519-1530.
24. Frid A, Hardebo JE: The thigh may not be suitable as an injection site for
patients self-injecting sumatriptan. Neurology 1997, 49(2):559-61.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/11/126/prepub
doi:10.1186/1471-2377-11-126
Cite this article as: Phillips et al.: An open-label, multicenter study to
evaluate the safe and effective use of the single-use autoinjector with
an Avonex
®® prefilled syringe in multiple sclerosis subjects. BMC
Neurology 2011 11:126.
Phillips et al. BMC Neurology 2011, 11:126
http://www.biomedcentral.com/1471-2377/11/126
Page 9 of 9